![Kenneth Hoberman](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Kenneth Hoberman
Geschäftsführer bei
STEMLINE THERAPEUTICS, INC.
Vermögen: 18 Mio $ am 30.06.2026
Profil
Kenneth Hoberman is Vice Chairman at Lirum Therapeutics, Inc. since 2021.
Mr. Hoberman is Independent Director at TG Therapeutics, Inc. since 2014.
Mr. Hoberman is Independent Director at Nuvectis Pharma, Inc. since 2021.
Mr. Hoberman is Chief Operating Officer at Stemline Therapeutics, Inc. since 2013.
Mr. Hoberman was Vice President-Corporate & Business Development at Keryx Biopharmaceuticals, Inc. from 2004 to 2012.
Mr. Hoberman completed undergraduate studies at Boston University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
TG THERAPEUTICS, INC. 0,18 % | 11.06.2026 | 279.653 ( 0,18 % ) | 15 Mio $ | 30.06.2026 |
NUVECTIS PHARMA, INC. 0,63 % | 11.06.2026 | 168.140 ( 0,63 % ) | 3 Mio $ | 30.06.2026 |
Aktive Positionen von Kenneth Hoberman
| Unternehmen | Position | Beginn |
|---|---|---|
| STEMLINE THERAPEUTICS, INC. | Geschäftsführer | 01.01.2013 |
| TG THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 15.12.2014 |
| NUVECTIS PHARMA, INC. | Direktor/Vorstandsmitglied | 01.07.2021 |
| LIRUM THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 01.11.2021 |
Ehemalige bekannte Positionen von Kenneth Hoberman
| Unternehmen | Position | Ende |
|---|---|---|
| KERYX BIOPHARMACEUTICALS | Corporate Officer/Principal | 01.01.2012 |
Ausbildung von Kenneth Hoberman
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
31
Beziehungen ersten Grades
6
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 6 |
|---|---|
TG Therapeutics, Inc.
 TG Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company | Health Technology |
Keryx Biopharmaceuticals, Inc.
 Keryx Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which focuses on therapies for patients with renal disease | Health Technology |
Stemline Therapeutics, Inc.
 Stemline Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes novel oncology therapeutics | Health Technology |
Boston University
 Boston University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Nuvectis Pharma, Inc.
 Nuvectis Pharma, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which develops medicines for treatment of cancer | Health Technology |
Lirum Therapeutics, Inc.
 Lirum Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company that focuses on the treatment of debilitating diseases | Health Technology |
